Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies (vol 10, e003024, 2022)

被引：0
|
作者：
Michielin, O.
Lalani, A.
Robert, C.
机构：
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷 / 12期
关键词：
D O I：
10.1136/jitc-2021-003024corr1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 43 条
  • [1] Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
    Michielin, Olivier
    Lalani, Aly-Khan
    Robert, Caroline
    Sharma, Padmanee
    Peters, Solange
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (01)
  • [2] TACE plus immune checkpoint inhibitor-based systemic therapies for hepatocellular carcinoma
    Reiter, Florian P.
    Geier, Andreas
    LANCET, 2025, 405 (10474): : 174 - 176
  • [3] Effects of immune checkpoint inhibitor-based combination therapies on the gut microbiota in advanced melanoma patients
    Li, J.
    Xu, L.
    Peng, Z.
    Jiang, H.
    Chao, F.
    Ding, Y.
    Moll, J. M.
    Li, D.
    Wen, X.
    Wang, J.
    Ding, Q.
    Zhang, L.
    Kristiansen, K.
    Brix, S.
    Zhang, X.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S934 - S934
  • [4] Predictive Biomarkers of Immune Checkpoint Inhibitor-Based Mono- and Combination Therapies for Hepatocellular Carcinoma
    Jeng, Long-Bin
    Wang, John
    Teng, Chiao-Fang
    JOURNAL OF CANCER, 2024, 15 (02): : 484 - 493
  • [5] Dermatological adverse events associated with immune checkpoint inhibitor-based combinations of anticancer therapies: a systematic review
    Salloum, Antoine
    Habre, Maya
    Chebl, Joanna Abi
    Chebl, Karen Abi
    Atallah, Carl
    Medawar, Georgio
    Kourie, Hampig R.
    IMMUNOTHERAPY, 2022, 14 (06) : 489 - 503
  • [6] Mathematical modelling of tumour-immune interactions in presence of checkpoint inhibitor-based therapies for the treatment of cancer
    Arora, Vaibhav
    Ali, Sk Meheraj
    Das Karmakar, Arka
    Sen, Pramita
    MATERIALS TODAY-PROCEEDINGS, 2022, 57 : 1477 - 1483
  • [7] Letter to the editor: Hepatitis B virus reactivation in immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma
    Jin, Zhi-Cheng
    Chen, Jian-Jian
    Luo, Biao
    Zhang, Wei-Hua
    Teng, Gao-Jun
    HEPATOLOGY, 2023, 77 (01) : E5 - E6
  • [8] Case report: Diverse immune responses in advanced pancreatic ductal adenocarcinoma treated with immune checkpoint inhibitor-based conversion therapies
    Li, Xiaoying
    Xiao, Chaoxin
    Li, Ruizhen
    Zhang, Pei
    Yang, Heqi
    Cao, Dan
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [9] Adverse Events of Immune Checkpoint Inhibitor-Based Therapies for Unresectable Hepatocellular Carcinoma in Prospective Clinical Trials: A Systematic Review and Meta-analysis
    Zhang, Yizhou
    Wang, Minghao
    Chen, Qichen
    Deng, Yiqiao
    Chen, Jinghua
    Dai, Yimin
    Luo, Sheng
    Xu, Jianming
    Zhao, Hong
    Cai, Jianqiang
    LIVER CANCER, 2023, 12 (06) : 521 - 538
  • [10] FIRST-LINE IMMUNE CHECKPOINT INHIBITOR-BASED SEQUENTIAL THERAPIES FOR ADVANCED HEPATOCELLULAR CARCINOMA: A RATIONALE FOR FUTURE TRIALS
    Cabibbo, G.
    Celsa, C.
    Battaglia, S.
    Enea, M. .
    Rizzo, G. E. M.
    Busacca, A.
    Petta, S.
    Calvaruso, V.
    Di Marco, V.
    Craxi, A.
    Camma, C.
    DIGESTIVE AND LIVER DISEASE, 2021, 53 : S107 - S107
12345